Equity Profile
Post-Earnings Recap
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.03 | N/A | -1.98% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.03 | N/A | -1.98% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed caution regarding the company's near-term performance. They reiterated their focus on strategic initiatives to drive future growth.
Management highlighted ongoing challenges in the current market environment.
They emphasized a commitment to long-term growth despite short-term setbacks.
Ionis Pharmaceuticals reported a larger-than-expected loss in EPS, which contributed to a 3.38% decline in stock price following the earnings announcement. The lack of revenue figures and guidance may raise concerns among investors about the company's current performance and future prospects. Management's defensive tone suggests they are navigating through challenges but remain focused on long-term strategies.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SoFi Technologies, Inc.